B cell targeted therapies in inflammatory autoimmune disease of the central nervous system

Frontiers in Immunology

Immunology

Ron Milo¹  Sven G. Meuth²  Heike Blum²  Michael Dietrich²  Moritz J. Furman²  Philipp Albrecht³  Hans-Peter Hartung⁴  Jan Mares⁵ 

[1] Department of Neurology, Barzilai Medical Center, Ashkelon, Israel;Department of Neurology, Heinrich-Heine University Düsseldorf, Medical Faculty, Düsseldorf, Germany;Department of Neurology, Heinrich-Heine University Düsseldorf, Medical Faculty, Düsseldorf, Germany;Department of Neurology, Maria Hilf Clinic, Moenchengladbach, Germany;Department of Neurology, Heinrich-Heine University Düsseldorf, Medical Faculty, Düsseldorf, Germany;Department of Neurology, Palacky University in Olomouc, Olomouc, Czechia;Brain and Mind Center, Medical Faculty, The University of Sydney, Sydney, NSW, Australia;Department of Neurology, Palacky University in Olomouc, Olomouc, Czechia;

关键词: B cell depletion;    multiple sclerosis (MS);    neuromyelitisoptica spectrum disorders (NMOSD);    myelin oligodendrocyte glycoprotein associated autoimmune disease (MOGAD);    autoimmune disease of the central nervous system;   

DOI  :  10.3389/fimmu.2023.1129906

 received in 2022-12-22, accepted in 2023-02-23,  发布年份 2023

来源: Frontiers

【 摘 要 】

Cumulative evidence along several lines indicates that B cells play an important role in the pathological course of multiple sclerosis (MS), neuromyelitisoptica spectrum disorders (NMOSD) and related CNS diseases. This has prompted extensive research in exploring the utility of targeting B cells to contain disease activity in these disorders. In this review, we first recapitulate the development of B cells from their origin in the bone marrow to their migration to the periphery, including the expression of therapy-relevant surface immunoglobulin isotypes. Not only the ability of B cells to produce cytokines and immunoglobulins seems to be essential in driving neuroinflammation, but also their regulatory functions strongly impact pathobiology. We then critically assess studies of B cell depleting therapies, including CD20 and CD19 targeting monoclonal antibodies, as well as the new class of B cell modulating substances, Bruton´s tyrosinekinase (BTK) inhibitors, in MS, NMOSD and MOGAD.

【 授权许可】

Unknown   
Copyright © 2023 Furman, Meuth, Albrecht, Dietrich, Blum, Mares, Milo and Hartung